All companies
Visit website
TargaZyme
OperatingTargaZyme, Inc
Healthcare · Biotech · Founded 2005
Next frontier of cancer medicine
Post-money valuation ⓘ
$196.1M
As of Sep 2022 · from TargaZyme Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$116,190
Across 2 rounds since 2022
Latest share price
$6.62
TargaZyme Common Stock 1 offering price
Financials
FY2020–FY2021 · from SEC filings · hover any figure for its source$0
−$2.5M
2020
$0
−$2.4M
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$2,483,254
-$2,416,916
Taxes paid
$0
$0
Balance sheet
Cash
$19,562
$111,900
Accounts receivable
$0
$0
Total assets
$3,455,588
$3,174,319
Short-term debt
$7,336,075
$7,524,097
Long-term debt
$203,700
$441,014
Total liabilities
$7,539,775
$7,965,111
Other
Headcount
—
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$196.3M
post-money
$196.1M
post-money
Reg CF Offering (2022)
TargaZyme Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $73.2K / $1.1MInvestors 83Post-money $196.1M
Raised $42.9K / $1.1MInvestors 81Post-money $196.3M
Reg CF annual-report compliance
Delinquent
Filed 0 of 4 annual reports (FY2022–FY2025)
Missing: 2022, 2023, 2024, 2025
83 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001929815Share price $6.62
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.